



RESEARCH

Open Access



# Perceptions and experiences of COVID-19 vaccines' side effects among healthcare workers at an Egyptian University Hospital: a cross-sectional study

Hisham Ahmed Orebi<sup>1</sup>, Hesham Elsayed Emar<sup>1</sup>, Abdallah Ahmoud Alhindi<sup>1</sup>, Mohamed Reda Shahin<sup>1</sup>, Arwa Hassan Hegazy<sup>1</sup>, Ibrahim Ali Kabbash<sup>2</sup>  and Shima M. Saied<sup>2\*</sup> 

## Abstract

**Background:** A safe and effective vaccine is the ultimate key to mitigating the COVID-19 pandemic. Vaccine acceptance is influenced by various factors, including perceptions about the vaccine's safety and side effects. The side effects vary depending on the type of the vaccine, but they are mainly mild, local, temporary, and self-limiting.

**Methods:** A cross-sectional study was carried out at Tanta University Hospitals, including 1246 healthcare workers who received either the first or the second dose of the COVID-19 vaccine, selected via a systematic random sampling technique using a self-administered structured validated questionnaire for data collection from November 2021 to January 2022. Qualitative data were presented as frequencies and percentages and analyzed using Chi-square and Fisher's exact tests.

**Results:** The prevalence of one or more side effects was 91.3%. Among participants, about two-thirds believed in vaccine safety and its necessity (65.4% and 63.6%, respectively). Significantly more participants (46.9%) were concerned about AstraZeneca thrombotic complications than other vaccine types. The top five side effects reported by participants were injection site pain (64.8%), sense of fatigue (57.1%), headache (49.9%), muscle pain (48.7%), and fever (46.5). Most of the side effects were significantly higher among participants vaccinated with AstraZeneca. Side effects impacted work capacity of 23.4%, which was significantly higher among participants who received AstraZeneca (33.6%).

**Conclusion:** Participants had a good level of belief in vaccination safety and necessity. Healthcare workers who got the AstraZeneca vaccination reported more adverse effects than other vaccines. Injection site pain, fatigue, headache, muscle pains, and fever were the most frequently reported side effects. More research on vaccination safety is needed to understand the long-term adverse effects of vaccinations better, improve the public trust, and accelerate vaccine adoption.

**Keywords:** COVID-19, Vaccine, Side effects, Healthcare workers, Egypt

## Background

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for coronavirus disease (COVID-19), is a global crisis that has hit worldwide since its emergence in December 2019 [1]. Infected

\*Correspondence: ShimaSaied@med.Tanta.edu.eg

<sup>2</sup> Public Health and Community Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt  
Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

individuals may have mild symptoms, such as fever, cough, myalgia, and fatigue, or may suffer from pneumonia, multiple organ failure, and die in some cases [2]. Healthcare workers (HCWs) are at risk of contracting COVID-19 [3]. Besides the increased mortality risk, various studies have revealed that COVID-19 hurts HCWs' psychological and well-being status [4]. A systematic review reported the prevalence of COVID-19-positive HCWs throughout the early months of the COVID-19 pandemic as 51.7%, and a multicenter study from Egypt demonstrated the seroprevalence of anti-SARS-CoV-2 antibodies as 46.3% [5, 6]. We are experiencing a rapid spread due to SARS-CoV-2 because of its continuous mutations and quickly spreading infection [7]. Thus, a safe and effective vaccine is the ultimate key in mitigating the COVID-19 pandemic [8].

The start of the COVID-19 vaccine rollout in December 2020 was a landmark in the history of the fight against this pandemic; thus, it was recommended that the pandemic history be divided into pre-vaccination and post-vaccination periods [9]. Vaccine hesitancy is a major public health concern, fueled by rumors and misinformation about vaccine effectiveness and safety [10]. Vaccine acceptance can be influenced by various factors, including knowledge of the vaccine, perceptions about its adverse effects, attitude toward vaccination, perceived vulnerability to illness, social impacts, trust in the healthcare profession, and increased vaccine information [11]. A large-scale multinational study concluded that the highest rates of vaccination hesitancy were found among HCWs from the Arab world's western areas (Egypt, Morocco, Tunisia, and Algeria). Concerns about adverse effects were the most often reported reason for hesitancy [12]. The different types of the available vaccines are mRNA vaccines (Pfizer BioNTech, Moderna, and Johnson & Johnson), viral vector vaccines (AstraZeneca, Sputnik V), and inactivated vaccines (Sinopharm, Sinovac, and COVAXIN) are among the COVID-19 vaccines now widely available for usage worldwide [13]. Understanding the potential side effects of vaccination is essential for all groups engaged in the process, including the individual who receives the vaccine, caregivers, and healthcare providers [14]. Maximizing the COVID-19 vaccination rate among healthcare workers (HCWs) is an evidence-based, reasonable approach to public health priorities [15]. Healthcare workers' awareness of the significance of vaccination programs influences their attitudes towards public health preventive measures, especially when considering a long-term anti-COVID-19 strategy requiring future doses of booster vaccinations [16]. Furthermore, healthcare practitioners serve as the general public's guide and trusted source of vaccination information. They can guard against false and confusing

information. As a result, their attitude will influence their own and others' health [17]. Previous research on the side effects of the COVID-19 vaccine found mild-to-moderate side effects, with the severity of adverse effects varying depending on the type of COVID-19 vaccine used [18]. Most of the reported side effects were moderate, such as fever, headache, local pain at the injection site, and muscle pain [19]. Since the development and availability of COVID-19 vaccinations, governments worldwide have actively worked to implement effective mass vaccination programs [20].

When the COVID-19 vaccine became available in Egypt, the Egyptian Ministry of Health (MOH) prioritized healthcare workers. They were the highest risk population for being infected with the new virus. The earliest vaccinated HCWs were given the Oxford–AstraZeneca COVID-19 vaccine until the all-available doses ran out, then they received the Sinopharm and Sinovac vaccines [17, 21]. According to WHO, until May 2022, Egypt had 513,790 confirmed COVID-19 cases, including 24,641 deaths, and a total of 82,017,392 vaccination doses were delivered [22]. A study of COVID-19 vaccines' side effects among the Egyptian population concluded that coronavirus vaccinations were well-tolerated and safe, with most post-vaccine adverse effects being mild to moderate [23].

Few studies [21, 23] were carried out to increase knowledge about the COVID-19 vaccine's adverse effects by enquiring about and assessing self-reported side effects across various demographic and medical characteristics. Therefore, the primary objective of this study was to assess the perceptions and the frequency of the experienced side effects of the early-vaccinated Tanta University Hospitals' HCWs regarding the received COVID-19 vaccinations. The secondary objectives were to identify the potential factors of COVID-19 vaccine side effects and their correlates.

## Methods

### Study design and settings

We carried out a comparative cross-sectional study in Tanta University Hospitals (TUHs) among HCWs who had been vaccinated with either the first or the second dose. The study was conducted from November 20th, 2021, to January 20th, 2022. Tanta University Hospitals are the largest medical facility located in Egypt's middle of the Nile Delta. Approximately 5100 nurses and technicians and 2800 physicians are working in TUHs.

### Participants

The inclusion criteria for this study were the HCWs (physicians, nurses, technicians, and others) in Tanta University Hospitals who have been vaccinated with the

COVID-19 vaccine since the vaccine's approval in Egypt. The HCWs who received the *Oxford -AstraZeneca*, *Sinopharm*, and *Sinovac* vaccines were included if they received either the first or second dose from March 2021 until January 2022 by the time of filling out the questionnaire. Nearly 95% of them were vaccinated with either AstraZeneca, Sinopharm, or Sinovac vaccines by the time of this study. We excluded only healthcare workers who did not receive the vaccine during the study period. The sample size was calculated using Epi Info 7 software. The criteria of sample size calculation were based on 95% confidence limit, the prevalence of complications at 85%, as expressed by three experts working in the vaccination center of TUHs, with a margin of error of 3% and a design effect of two. The calculated sample size was found to be 1088. We recruited 1246 participants to compensate for any incomplete questionnaires. We selected study participants by systematic sampling.

### Study tool

A structured self-administered questionnaire, adapted from Kim et al. study in China [24]. The questionnaire was reviewed and pilot tested on 30 HCWs to check the acceptability and clarity of the questions. The pilot responses were not included in the final analysis. We calculated Cronbach's alpha for internal consistency and found it at 0.711. A panel of seven experts tested content and face validity. The experts were asked independently to review each item using 4 points ordinal scale (one = disagree, two = need modification, three = agree, four = highly agree). The content validity index was estimated. To obtain the content validity index at the item level, the number of experts judging the item as relevant or clear (rating 3 or 4) was divided by the total number of experts. The item will be suitable if it exceeds 0.79.

The questionnaire included four main sections addressing the following data:

*Section I* includes demographic data such as age, sex, occupation, smoking status, and smoking duration, if present. With three questions asking about the received vaccine and the presence of chronic diseases,

*Section II* This section aimed to assess the adverse effects shortly after receiving the COVID-19 vaccine (within 72 h). The healthcare worker was able to choose from 23 questions enumerating adverse effects that WHO and other studies have previously documented following vaccination, with the possibility to add any non-mentioned side effects and a question asking about the duration of the experienced side effects. For the occurrence of each side effect, the respondents answered yes or no.

*Section III* included three questions about previous COVID-19 infections, either diagnosed or experienced

suspected symptoms without a diagnosis. Participants answered the question by yes or no, and for the question of diagnosis, they mentioned the method of diagnosis.

*Section IV* contained four questions answered by "agree" or "disagree" to measure the perception and knowledge of the vaccines and their opinion on vaccine safety.

Data collection was through direct interviewing of the study participants. The questionnaire was self-administered, and the data collectors were present to fill it in and explain any queries.

### Statistical analysis

The collected data were organized, tabulated, and statistically analyzed using SPSS version 19 (Statistical Package for Social Studies) created by IBM, Illinois, Chicago, USA. The range, mean, and standard deviation were calculated for numerical values. The number and percentage were calculated for categorical variables, and the Chi-squared test tested differences between subcategories. If in 20% or more of the cells, the number of expected counts is less than five, Fisher's exact test was used instead. The level of significance was adopted at  $p < 0.05$ .

### Results

The total number of studied healthcare workers was 1246. Participants who received the AstraZeneca vaccine were relatively younger ( $34.4 \pm 11.45$ ) than their peers receiving other vaccines ( $37.8 \pm 11.83$  and  $35.0 \pm 11.31$ ). The highest frequency of the age group 20–30 received AstraZeneca (45.5%). Meanwhile, among other age categories, the highest frequency received Sinopharm. The distribution of age groups in relation to the type of vaccines was significantly different. Concerning sex, the highest frequency of males (52.7%) received AstraZeneca, and differences in the type of vaccination in relation to sex were statistically significant. The distribution of participants in relation to the type of vaccination and job was statistically significant, with the highest frequency of physicians (46.6%) who received AstraZeneca. The highest frequency of smokers received Sinopharm (66.7%). Those receiving two doses of AstraZeneca were 39.6%, significantly higher than 36.0% and 24.4% for the two other vaccines. The presence of chronic diseases did not significantly affect the type of vaccine received. More than one-fourth (26.8%) reported a previously confirmed COVID-19 infection. However, there are no significant differences in the type of vaccination in relation to previous experience with COVID-19 infections (Table 1).

Nearly two-fifths of participants (65.4%) believed in vaccine safety. Significantly, more participants (46.9%) who received AstraZeneca were concerned about thrombotic complications. Trust in governmental policy for

**Table 1** Distribution of studied health care workers by type of vaccine

| Variables                   | AstraZeneca      |      | Sinopharm        |      | Sinovac          |      | Total             |     | $\chi^2$ | p      |
|-----------------------------|------------------|------|------------------|------|------------------|------|-------------------|-----|----------|--------|
|                             | n                | %    | n                | %    | n                | %    | n                 | %   |          |        |
| Age in years                |                  |      |                  |      |                  |      |                   |     |          |        |
| 20                          | 258              | 45.4 | 154              | 27.1 | 156              | 27.5 | 568               | 100 | 72.624   | <0.001 |
| 30                          | 39               | 18.2 | 111              | 51.9 | 64               | 29.9 | 214               | 100 |          |        |
| 40                          | 86               | 34.4 | 94               | 37.6 | 70               | 28.0 | 250               | 100 |          |        |
| 50                          | 62               | 31.6 | 94               | 48.0 | 40               | 20.4 | 196               | 100 |          |        |
| 60                          | 5                | 27.8 | 8                | 44.4 | 5                | 27.8 | 18                | 100 |          |        |
| Range                       | 20–63            |      | 20–63            |      | 20–63            |      | 20–63             |     |          |        |
| Mean $\pm$ SD               | 34.4 $\pm$ 11.45 |      | 37.8 $\pm$ 11.83 |      | 35.0 $\pm$ 11.31 |      | 35.80 $\pm$ 11.65 |     |          |        |
| Sex                         |                  |      |                  |      |                  |      |                   |     |          |        |
| Males                       | 147              | 52.7 | 76               | 27.2 | 56               | 20.1 | 279               | 100 | 42.800   | <0.001 |
| Females                     | 303              | 31.3 | 385              | 39.8 | 279              | 28.9 | 967               | 100 |          |        |
| Job                         |                  |      |                  |      |                  |      |                   |     |          |        |
| Physicians                  | 271              | 46.6 | 163              | 28.1 | 147              | 25.3 | 581               | 100 | 65.378   | <0.001 |
| Nurses                      | 146              | 26.0 | 256              | 45.6 | 160              | 28.5 | 562               | 100 |          |        |
| Technicians                 | 24               | 34.3 | 32               | 45.7 | 14               | 20.0 | 70                | 100 |          |        |
| Others                      | 9                | 27.3 | 10               | 30.3 | 14               | 42.4 | 33                | 100 |          |        |
| Smoking                     |                  |      |                  |      |                  |      |                   |     |          |        |
| Non-smokers                 | 444              | 36.7 | 437              | 36.1 | 329              | 27.2 | 1210              | 100 | 14.142   | 0.001  |
| Smokers                     | 6                | 16.7 | 24               | 66.7 | 6                | 16.7 | 36                | 100 |          |        |
| Doses                       |                  |      |                  |      |                  |      |                   |     |          |        |
| One                         | 103              | 27.9 | 145              | 39.3 | 121              | 32.8 | 369               | 100 | 14.314   | <0.001 |
| Two                         | 347              | 39.6 | 316              | 36.0 | 214              | 24.4 | 877               | 100 |          |        |
| Diabetes                    |                  |      |                  |      |                  |      |                   |     |          |        |
| Negative                    | 439              | 36.3 | 446              | 36.9 | 323              | 26.7 | 1208              | 100 | 0.944    | 0.624  |
| Positive                    | 11               | 28.9 | 15               | 39.5 | 12               | 31.6 | 38                | 100 |          |        |
| Hypertension                |                  |      |                  |      |                  |      |                   |     |          |        |
| Negative                    | 435              | 36.5 | 437              | 36.7 | 320              | 26.8 | 1192              | 100 | 1.949    | 0.377  |
| Positive                    | 15               | 27.8 | 24               | 44.4 | 15               | 27.8 | 54                | 100 |          |        |
| Allergy                     |                  |      |                  |      |                  |      |                   |     |          |        |
| Negative                    | 440              | 36.3 | 448              | 37.0 | 324              | 26.7 | 1212              | 100 | 0.838    | 0.658  |
| Positive                    | 10               | 29.4 | 13               | 38.2 | 11               | 32.4 | 34                | 100 |          |        |
| Previous COVID-19 infection |                  |      |                  |      |                  |      |                   |     |          |        |
| None                        | 295              | 37.0 | 288              | 36.1 | 215              | 26.9 | 798               | 100 |          |        |
| Confirmed                   | 155              | 34.6 | 173              | 38.6 | 120              | 26.8 | 448               | 100 | 0.943    | 0.624  |
| Total                       | 450              | 36.1 | 461              | 37.0 | 335              | 26.7 | 1246              | 100 |          |        |

vaccinations and the necessity to get the vaccine were reported by 55.5% and 63.6% (Table 2).

The most frequently reported side effects were injection site pain (65.4%), fatigue (57.6%), headache (56.3%), and fever (45.1%). Nearly one-fourth (23.4%) of participants reported that side effects affected their working capacity. The majority (95.9%) reported the duration of side effects as being less than 2 weeks. Most side effects tend to be more frequently reported among participants receiving AstraZeneca than the other two vaccines (Table 3 and Fig. 1). Sex differences in relation to vaccine

side effects were not significant (Table 4). Again, side effects in relation to socio-demographic factors and the presence of chronic illness were not also found to be significant (Table 5).

## Discussion

This survey-based study aimed to assess the perceptions and frequency of self-reported side effects of Tanta University Hospitals' HCWs about COVID-19 vaccines and identify their associated factors. The vaccine's side effects could be classified as either local or systemic, with

**Table 2** Perceptions regarding the received vaccines among the participants


| Variables                                 | AstraZeneca<br>(n = 450) |      | Sinopharm<br>(n = 461) |      | Sinovac<br>(n = 335) |      | Total (n = 1246) |      | $\chi^2$ | p       |
|---|--------------------------|------|------------------------|------|----------------------|------|------------------|------|----------|---------|
|   | n                        | %    | n                      | %    | n                    | %    | n                | %    |          |         |
| Believe in the vaccine's safety           | 279                      | 66.0 | 301                    | 65.3 | 217                  | 64.8 | 815              | 65.4 | 0.132    | 0.936   |
| Concerned about thrombotic complications  | 211                      | 46.9 | 163                    | 35.4 | 114                  | 34.0 | 488              | 39.2 | 17.780   | < 0.001 |
| Trust governmental policy for vaccination | 256                      | 56.9 | 258                    | 56.0 | 178                  | 53.1 | 692              | 55.5 | 1.150    | 0.563   |
| Vaccine is necessary                      | 312                      | 69.3 | 302                    | 65.5 | 178                  | 53.1 | 792              | 63.6 | 22.955   | < 0.001 |

**Table 3** Self-reported side effects by type of vaccines

| Side effects                      | AstraZeneca<br>(n = 450) |      | Sinopharm<br>(n = 461) |      | Sinovac (n = 335) |      | Total (n = 1246) |      | $\chi^2$ | p       |
|-----------------------------------|--------------------------|------|------------------------|------|-------------------|------|------------------|------|----------|---------|
|                                   | n                        | %    | n                      | %    | n                 | %    | n                | %    |          |         |
| Fever                             | 336                      | 74.7 | 128                    | 27.8 | 116               | 34.6 | 580              | 46.5 | 227.50   | < 0.001 |
| Vomiting                          | 35                       | 7.8  | 29                     | 6.3  | 12                | 3.6  | 76               | 6.1  | 5.949    | 0.051   |
| Diarrhea                          | 41                       | 9.1  | 22                     | 4.8  | 20                | 6.0  | 83               | 6.7  | 7.247    | 0.027   |
| Headache                          | 286                      | 63.6 | 207                    | 44.9 | 129               | 38.5 | 622              | 49.9 | 55.056   | < 0.001 |
| Fatigue                           | 334                      | 74.2 | 220                    | 47.7 | 157               | 46.9 | 711              | 57.1 | 84.712   | < 0.001 |
| Chills                            | 165                      | 36.7 | 92                     | 20.0 | 65                | 19.4 | 322              | 25.8 | 43.093   | < 0.001 |
| Muscle pains                      | 285                      | 63.6 | 173                    | 37.5 | 148               | 44.2 | 607              | 48.7 | 65.525   | < 0.001 |
| Joint pains                       | 192                      | 42.7 | 97                     | 21.0 | 101               | 30.1 | 390              | 31.3 | 49.807   | < 0.001 |
| Urticaria                         | 19                       | 4.2  | 20                     | 4.3  | 3                 | 0.9  | 42               | 3.4  | 8.628    | 0.013   |
| Shortness of breathing            | 52                       | 11.6 | 27                     | 5.9  | 17                | 5.1  | 96               | 7.7  | 14.857   | 0.001   |
| Chest pain                        | 44                       | 9.8  | 33                     | 7.2  | 20                | 6.0  | 97               | 7.8  | 4.278    | 0.118   |
| Edema of arms or legs             | 12                       | 2.7  | 15                     | 3.3  | 9                 | 2.7  | 36               | 2.9  | 0.347    | 0.841   |
| Loss of appetite                  | 102                      | 22.7 | 42                     | 9.1  | 30                | 9.0  | 174              | 14.0 | 44.400   | < 0.001 |
| Dysphagia                         | 51                       | 11.3 | 21                     | 4.6  | 9                 | 2.7  | 81               | 6.5  | 28.179   | < 0.001 |
| Constipation                      | 12                       | 2.7  | 24                     | 5.2  | 12                | 3.6  | 48               | 3.9  | 4.055    | 0.132   |
| Bleeding under the skin           | 3                        | 0.7  | 9                      | 2.0  | 6                 | 1.8  | 18               | 1.4  | 3.030    | 0.220   |
| Bleeding from the nose            | 14                       | 3.1  | 3                      | 0.7  | 6                 | 1.8  | 23               | 1.8  | 7.616    | 0.022   |
| Injection site                    |                          |      |                        |      |                   |      |                  |      |          |         |
| Pain                              | 336                      | 74.7 | 254                    | 55.1 | 217               | 64.8 | 807              | 64.8 | 38.215   | < 0.001 |
| Redness                           | 164                      | 36.4 | 80                     | 17.4 | 49                | 14.6 | 293              | 23.5 | 66.271   | < 0.001 |
| Swelling                          | 183                      | 40.7 | 83                     | 18.0 | 68                | 20.3 | 334              | 26.8 | 69.496   | < 0.001 |
| Side effects affect work capacity | 151                      | 33.6 | 71                     | 15.4 | 70                | 20.9 | 292              | 23.4 | 43.474   | < 0.001 |
| Duration of symptoms              |                          |      |                        |      |                   |      |                  |      |          |         |
| < 2 weeks                         | 422                      | 93.8 | 444                    | 96.3 | 329               | 98.2 | 1195             | 95.9 | 12.010   | 0.017   |
| 2–4 weeks                         | 22                       | 4.9  | 11                     | 2.4  | 3                 | 0.9  | 36               | 2.9  |          |         |
| 4 weeks                           | 6                        | 1.3  | 6                      | 1.3  | 3                 | 0.9  | 15               | 1.2  |          |         |

severity ranging from mild to moderate. Regardless of the experienced side effects, most HCWs vaccine recipients accepted the challenge of stopping the fatal pandemic [25, 26]. The study participants accepted the vaccination due to their high degree of health literacy and scientific enthusiasm. Also, the expected benefits influenced respondents' decisions more than the expected adverse effects.

Many of the participant HCWs were young and females, which was similarly reported by Elgendy et al. Among the general Egyptian population, they stated that most of the participants were women and younger (< 40 years old), as they were more interested in taking part in the survey and sharing their experiences than the other groups. This could also be because young



people and women are more susceptible to post-vaccine adverse effects than seniors and males [22].

In our study, nearly half (48%) of the over-50-year-old participants received the inactivated Sinopharm vaccine. This is evidenced by a study of the efficacy and safety in older age groups, which concluded that inactivated COVID-19 vaccinations revealed promising antibody responses with fewer side effects [27]. The current study showed that the highest percentage of viral vector-based AstraZeneca vaccine uptake was among the youngest age group. This comes in accordance with Dziedzic et al. study, as most recipients of AstraZeneca vaccine were in the younger age group than in the older one [28].

The highest percentage (52.7%) of male participants received AstraZeneca vaccine in this study, while the highest percentage (39.8%) of females received Sinopharm vaccine; this may be attributed to some reports of the occurrence of potential thrombotic episodes in females [29]. However, the World Health Organization's and European Medicines Agency's (EMA) assured no indication that Oxford–AstraZeneca vaccine was associated with thromboembolic events [30, 31]. The issue of

potential thromboembolic events to AstraZeneca vaccine is challenging to decide the causality from a coincidence since the COVID-19 infection is also linked with blood clotting [32, 33].

The current study revealed that the inactivated Sinopharm vaccine was the most frequently used type among HCWs with chronic morbidities such as diabetes, hypertension, and allergies rather than the viral vector-based AstraZeneca vaccine as recommended by the Egyptian MOH regarding the selection of the type of vaccine according to the medical history of the recipient taken before vaccination. These findings are consistent with WHO recommendations for the safety and effectiveness of inactivated vaccines for the vaccination of individuals having comorbidities or underlying diseases that put them at risk of developing severe COVID-19 disease [34].

In our study, most participants believed in the vaccine's safety and confirmed its necessity because of their scientific and medical backgrounds. This was in agreement with Raude et al. who stated that HCWs have a favorable attitude regarding COVID-19 vaccines [35]. Because of their continuous interaction with COVID-19 patients

**Table 4** Self-reported side effects by sex

| Side effects            | Males (n = 279) |      | Females (n = 967) |      | $\chi^2$ | p      |
|-------------------------|-----------------|------|-------------------|------|----------|--------|
|                         | n               | %    | n                 | %    |          |        |
| Systemic side effects   |                 |      |                   |      |          |        |
| Fever                   | 160             | 57.3 | 420               | 43.4 | 16.849   | <0.001 |
| Vomiting                | 19              | 6.8  | 57                | 5.9  | 0.317    | 0.573  |
| Diarrhea                | 25              | 9.0  | 58                | 6.0  | 3.057    | 0.080  |
| Headache                | 132             | 47.3 | 490               | 50.7 | 0.978    | 0.323  |
| Fatigue                 | 171             | 61.3 | 540               | 55.8 | 2.623    | 0.105  |
| Chills                  | 107             | 38.4 | 215               | 22.2 | 29.351   | <0.001 |
| Muscle pains            | 158             | 56.6 | 449               | 46.4 | 9.014    | 0.003  |
| Joint pains             | 92              | 33.0 | 298               | 30.8 | 0.469    | 0.493  |
| Urticaria               | 8               | 2.9  | 34                | 3.5  | 0.280    | 0.597  |
| Shortness of breathing  | 21              | 7.5  | 75                | 7.8  | 0.016    | 0.899  |
| Chest pain              | 20              | 7.2  | 77                | 8.0  | 0.190    | 0.663  |
| Edema of arms or legs   | 6               | 2.2  | 30                | 3.1  | 0.699    | 0.403  |
| Loss of appetite        | 55              | 19.7 | 119               | 12.3 | 9.888    | 0.002  |
| Dysphagia               | 31              | 11.1 | 50                | 5.2  | 12.571   | <0.001 |
| Constipation            | 12              | 4.3  | 36                | 3.7  | 0.195    | 0.658  |
| Bleeding under the skin | 3               | 1.1  | 15                | 1.6  | FET      | 0.591  |
| Bleeding from the nose  | 12              | 4.3  | 11                | 1.1  | 11.960   | 0.001  |
| Injection site          |                 |      |                   |      |          |        |
| Pain                    | 175             | 62.7 | 632               | 65.4 | 0.658    | 0.417  |
| Redness                 | 64              | 22.9 | 229               | 23.7 | 0.066    | 0.797  |
| Swelling                | 71              | 25.4 | 263               | 27.2 | 0.338    | 0.561  |

FET Fisher's Exact test

and the need to protect themselves from the risk of infection, HCWs have a positive attitude towards vaccination. According to the health belief model (HBM), which includes belief in the efficacy, perceived benefits, and perceived vulnerability to COVID-19, which is used to drive vaccination, these findings emphasize the importance of spreading clear, accurate, and comprehensive information by every possible means, like mass media and health education campaigns to motivate vaccination. This positive attitude of Egyptian HCWs appears to be consistent with the attitude of medical professionals in the UK and Poland, as the majority of respondents agreed that vaccination against COVID-19 is highly recommended and proved pro-vaccine behaviors, as seen in other countries. In addition, the findings of a survey conducted by Babicki et al. revealed that persons with a higher level of education and healthcare personnel have a more favorable attitude towards the COVID-19 vaccination [36–40].

The present study's most frequently reported side effects were injection site pain, fatigue, headache, fever, joint pain, and injection site swelling. Similar findings were reported by various published studies, which reported that the most common post-vaccination side

effects were pain, swelling at the vaccine injection site, fatigue, muscle, and joint pain, lethargy, dizziness, fever, and headache [22, 41].

The most commonly reported side effect among the studied HCWs who received the three types of vaccines was fatigue. Many Egyptian, large-scale Arab world and global studies concluded that fatigue was one of the most prevalent s observed following COVID-19 vaccination [4, 22, 28, 42–44].

Our study showed that HCWs who got the viral vector AstraZeneca vaccine were more likely to experience post-vaccination systemic and local side effects that influenced the work capacity in one-third of participants compared to those who received Sinopharm and Sinovac vaccines. This was in line with Zahid's study in Bahrain, which revealed that AstraZeneca had more side effects when compared to Sinopharm vaccine [42]. Among participants who received Oxford–AstraZeneca vaccine, the most overall self-reported side effects were fever, injection site pain, and fatigue, which were similarly reported among Saudi HCWs [43].

Also, the most frequent side effects among participants who received Sinopharm were pain in the injection site and fatigue, which is consistent with other

**Table 5** Potential factors associated with COVID-19 vaccine side effects

| Variables    | Side effect of COVID-19 vaccines |      |             |      | $\chi^2$ | p     |
|--------------|----------------------------------|------|-------------|------|----------|-------|
|              | No side effects                  |      | Side effect |      |          |       |
|              | n                                | %    | n           | %    |          |       |
| Age in years |                                  |      |             |      |          |       |
| 20           | 49                               | 8.6  | 519         | 91.4 | 6.968    | 0.138 |
| 30           | 18                               | 8.4  | 196         | 91.6 |          |       |
| 40           | 16                               | 6.4  | 234         | 93.6 |          |       |
| 50           | 25                               | 12.8 | 171         | 87.2 |          |       |
| 60           | 3                                | 16.7 | 15          | 83.3 |          |       |
| Sex          |                                  |      |             |      | 2.674    | 0.102 |
| Males        | 18                               | 6.5  | 261         | 93.5 |          |       |
| Females      | 93                               | 9.6  | 874         | 90.4 |          |       |
| Job          |                                  |      |             |      | 4.372    | 0.224 |
| Physicians   | 51                               | 8.8  | 530         | 91.2 |          |       |
| Nurses       | 46                               | 8.2  | 516         | 91.8 |          |       |
| Technicians  | 11                               | 15.7 | 59          | 84.3 |          |       |
| Others       | 3                                | 9.1  | 30          | 90.9 |          |       |
| Smoking      |                                  |      |             |      | FE       | 0.765 |
| Non-smokers  | 109                              | 9.0  | 1101        | 91.0 |          |       |
| Smokers      | 2                                | 5.6  | 34          | 94.4 |          |       |
| Doses        |                                  |      |             |      | 1.782    | 0.182 |
| One          | 39                               | 10.6 | 330         | 98.4 |          |       |
| Two          | 72                               | 8.2  | 805         | 91.8 |          |       |
| Diabetes     |                                  |      |             |      | FE       | 0.769 |
| Negative     | 107                              | 8.9  | 1101        | 91.1 |          |       |
| Positive     | 4                                | 10.5 | 34          | 89.5 |          |       |
| Hypertension |                                  |      |             |      | FE       | 0.810 |
| Negative     | 106                              | 8.9  | 1086        | 91.1 |          |       |
| Positive     | 5                                | 9.3  | 49          | 90.7 |          |       |
| Allergy      |                                  |      |             |      | FE       | 0.762 |
| Negative     | 109                              | 9.0  | 1103        | 91.0 |          |       |
| Positive     | 2                                | 5.9  | 32          | 94.1 |          |       |
| Total        | 111                              | 8.9  | 1135        | 91.1 |          |       |

Fisher's exact test

studies conducted to report the adverse effects of Sinopharm vaccine [22, 45].

Pain at the injection site was the most common local side effect experienced by participants who received the Sinovac vaccine, similarly reported by a Turkish study among nurses vaccinated with Sinovac [46]. To alleviate this very common adverse effect, it is recommended to lower the patient's arm to be injected to reduce pain. An injection into a relaxed muscle causes minor discomfort compared to injection into a tense one. Vaccines should also be stored at a low temperature; the Sinopharm COVID-19 vaccine should be stored at a normal refrigerator temperature. Injections without

adequate warming may increase the likelihood of pain at the injection site [18, 43].

Most participants' side effects were temporary and lasted from days to less than 2 weeks. This finding supports the fact that the majority of the post-COVID-19 vaccination adverse effects are self-limiting, and the recipients recover promptly; none of the symptoms is severe enough to necessitate hospitalization. According to the vaccine recipients in many studies, the post-vaccine symptoms are usually minimal. The symptoms were minor, insignificant, and did not threaten their lives [22, 41, 47].



The highest frequency of vaccine-related side effects was reported among the age group from 40 to less than 50 years. This is in coherence with an Iraqi study that revealed that middle-aged HCWs were more at risk of adverse vaccination effects [48].

Concerning gender-based discrepancy of the vaccines' side effects, male participants reported higher frequencies of side effects, especially the systemic ones, than females. These findings are in line with the results of a similar study among Polish HCWs, which reported that male participants had a greater rate of common mild systemic adverse events [28]. In contrast, female participants experienced more frequent local adverse effects. Interestingly, Italian female HCWs had a more robust immunological response to the vaccine and higher serological markers following COVID-19 vaccination, implying a link with more frequent post-vaccination self-reported side effects [49]. Besides, selection and information bias may also play a role in developing gender-based discrepancies. Hence, gender-adjusted analyses are required when investigating the self-reported outcomes of COVID-19 vaccines [50]. The smoker participants had a higher percentage of post-vaccination side effects than the non-smoker HCWs. The same was found by Mohsin et al., who stated that smokers were 3.6 times significantly higher than non-smokers to report side effects [51].

In the current study, HCWs reported a higher percentage of side effects than the second vaccination dose following the first dose. Like the findings of Khadka et al. a study in which participants experienced no more side effects following the second dose of vaccination than after the first [41].

In our study, HCWs with comorbid chronic conditions and allergies surprisingly demonstrated lower frequencies of COVID-19 vaccine-related side effects. This may be attributed to the fact that most of them received the safer inactivated vaccines. Chronic health problems were linked to a higher frequency of local and systemic vaccination-related side events. However, no definitive link has been shown between chronic diseases and the occurrence of post-vaccination side effects. It has been proposed that underlying or undetected health issues could influence adverse reactions to vaccination.

On the contrary, a weakened immune response due to comorbid disorders can be associated with decreased, attenuated immunological responsiveness, resulting in fewer adverse outcomes. In our study, HCWs with comorbid chronic conditions and allergies surprisingly demonstrated lower frequencies of COVID-19 vaccine-related side effects. This may be attributed to the fact that most of them received the safer inactivated vaccines. Chronic health problems were linked to a higher frequency of local and systemic vaccination-related

side events. However, no definitive link has been shown between chronic diseases and the occurrence of post-vaccination side effects. It has been proposed that underlying or undetected health issues could influence adverse reactions to vaccination. On the contrary, a weakened immune response due to comorbid disorders can be associated with decreased, attenuated immunological responsiveness, resulting in fewer adverse outcomes [28, 52, 53].

The study revealed that nearly all the side effects that occurred were similar to those reported in the literature, indicating that most COVID-19 vaccines' side effects are almost known at this time. The majority of them are non-life threatening, with most cases being mild to moderate in intensity and resolving in a few days. Good knowledge of vaccinations and their adverse effects was substantially related to the vaccination acceptance rate [44]. As a result, contradicting the rumors, misconceptions, and conspiracy theories regarding COVID-19 vaccinations and their real adverse effects could boost public trust and confidence in COVID-19 vaccines. Based on the results of the study, the following points are recommended:

1. Academic institutions should conduct further independent (non-sponsored) epidemiological research on the adverse effects of all available authorized COVID-19 vaccines, especially mRNA vaccines, which were not included in this study and after receiving the booster doses.
2. More independent community-based studies on vaccination safety are urgently needed to better understand the potential risk factors for vaccine side effects, boost public trust in vaccines, and accelerate their uptake.
3. As the vaccination campaign continues, there is a need to monitor additional reports on vaccines' short-term and long-term side effects.

One of the strengths of this study is that it is one of the earliest studies to investigate the COVID-19 vaccines' side effects among Egyptian HCWs. Obtaining sufficient and correct information about vaccines is essential to boost vaccination uptake. The current study provides authorities with in-depth insights into the anticipated challenges and issues. The first limitation of this study is that it was a single center using convenience sampling, which may restrict the generalizability of the findings. However, the large sample size could help increase the validity of the results. In addition, the use of self-reported data as the study investigators did not verify the receipt of vaccination doses by the participants, nor did they document their claimed symptoms,

which are subjective and may involve recall bias. In addition, the vaccine's latent effects were not investigated or included in this study.

## Conclusion

Overall, HCWs attitudes toward the national vaccination program were favorable. The most important conclusion is that with all three vaccines received by HCWs in this study—namely AstraZeneca, Sinopharm, and Sinovac—the first and second dose post-vaccination side effects were minor and predictable, mainly in the form of injection site pain, fatigue, headache, muscle pains, fever, joint pain, and injection site swelling. The study demonstrated that COVID-19 vaccinations approved in Egypt have a mainly safe profile, with mild and self-resolving side effects. The reported primarily non-life-threatening short-term adverse effects may contradict conspiracy theories and encourage vaccine-apprehensive public members about the vaccine's safety.

## Abbreviations

EMA: European Medicines Agency; HCWs: Health care workers; TUHs: Tanta University Hospitals; WHO: World Health Organization.

## Acknowledgements

The authors would like to thank the Tanta University Hospitals' health care workers who participated in the study for their engagement and cooperation.

## Author contributions

HAO, HEE, AAA, MRS, AHH shared in data collection, drafting, and writing of the manuscript. IAK was responsible for the concept of the paper and statistical analysis of data and shared in the writing and revision of the manuscript. SMS Participated in statistical analysis and was a major contributor to the manuscript's writing, editing and revision, and submission. All authors read and approved the final manuscript.

## Funding

Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB). This study did not receive any type of funding.

## Availability of data and materials

Data are available upon reasonable request from the corresponding author.

## Declarations

### Ethics approval and consent to participate

The Ethical Committee of Scientific Research in the Tanta Faculty of Medicine approved the research before starting the study (No. 34474/2/2021). For participants' consent, we inserted a written consent in the introductory page of the questionnaire, and all participants gave informed consent before answering the questions. Participation in this study was voluntary.

### Consent for publication

Not applicable.

### Competing interests

The authors declare no conflicts of interest.

## Author details

<sup>1</sup>Faculty of Medicine, Tanta University, Tanta, Egypt. <sup>2</sup>Public Health and Community Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt.

Received: 31 March 2022 Accepted: 22 May 2022

Published online: 30 May 2022

## References

- Shigemura J, Ursano RJ, Morganstein JC, Kurosawa M, Benedek DM. Public responses to the new coronavirus 2019 (2019-nCoV) in Japan: consequences for mental health and target populations. *Psychiatry Clin Neurosci*. 2020;74(4):281–2. <https://doi.org/10.1111/pcn.12988>.
- Zhonghua L, Xing B, Zhi Z. Novel coronavirus pneumonia emergency response epidemiology team. The epidemiological characteristics of an outbreak of. *Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention*. 2019. <https://doi.org/10.3760/cma.j.issn.0254-6450.2020.02.003>.
- Chou R, Dana T, Buckley DI, Selph S, Fu R, Totten AM. Epidemiology of and risk factors for coronavirus infection in health care workers: a living rapid review. *Ann Intern Med*. 2020;173(2):120–36. <https://doi.org/10.7326/L20-1134>.
- Alghamdi AA, Alkazemi A, Alissa A, Alghamdi I, Alwarafi G, Waggas HA. Adverse events following AstraZeneca COVID-19 vaccine in Saudi Arabia: a cross-sectional study among healthcare and nonhealthcare workers. *Intervirology*. 2022;65(2):104–9. <https://doi.org/10.1159/000519456>.
- Gholami M, Fawad I, Shadan S, Rowaiee R, Ghanem H, Khamis AH, Ho SB. COVID-19 and healthcare workers: a systematic review and meta-analysis. *Int J Infect Dis*. 2021;104:335–46.
- El-Sokkary RH, Daef E, El-Korashi LA, Khedr EM, Gad D, Mohamed-Hussein A, Zayed NE, Mostafa EF, Bahgat SM, Hassany SM, Amer MG. Seroprevalence of anti-SARS-CoV-2 antibodies among healthcare workers: a multicenter study from Egypt. *J Infect Public Health*. 2021;14(10):1474–80. <https://doi.org/10.1016/j.jiph.2021.09.011>.
- WHO Accelerating a safe and effective COVID-19 vaccine. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/accelerating-a-safe-and-effective-covid-19-vaccine>. Accessed on March 7th 2022.
- Alagoz O, Sethi AK, Patterson BW, Churpek M, Alhanaee G, Scaria E, Safdar N. The impact of vaccination to control COVID-19 burden in the United States: a simulation modeling approach. *PLoS ONE*. 2021;16(7):e0254456. <https://doi.org/10.1371/journal.pone.0254456>.
- Attia S, Howaldt HP. Impact of COVID-19 on the dental community: part I before vaccine (BV). *J Clin Med*. 2021;10(2):288. <https://doi.org/10.3390/jcm10020288>.
- Jarrett C, Wilson R, O'Leary M, Eckersberger E, Larson HJ. Strategies for addressing vaccine hesitancy—a systematic review. *Vaccine*. 2015;33(34):4180–90. <https://doi.org/10.1016/j.vaccine.2015.04.040>.
- Smith LE, Amlôt R, Weinman J, Yiend J, Rubin GJ. A systematic review of factors affecting vaccine uptake in young children. *Vaccine*. 2017;35(45):6059–69. <https://doi.org/10.1016/j.vaccine.2017.09.046>.
- Qunaibi E, Basheti I, Soudy M, Sultan I. Hesitancy of Arab healthcare workers towards COVID-19 vaccination: a large-scale multinational study. *Vaccines*. 2021;9(5):446. <https://doi.org/10.3390/vaccines9050446>.
- Callaway E. Coronavirus vaccines. *Nature*. 2020;580:577. <https://doi.org/10.1038/d41586-020-01221-y>.
- Herve C, Laupeze B, Giudice GD, Didierlaurent AM, Silva F. The how's and what's of vaccine reactogenicity. *NPJ Vaccines*. 2019. <https://doi.org/10.1038/s41541-019-0132-6>.
- World Health Organization Strategic Advisory Group of Experts on Immunization WHO SAGE Roadmap for Prioritizing uses of COVID-19 Vaccines in the Context of Limited Supply November 2020. Available online: <https://www.who.int/publications/i/item/who-sage-roadmap-for-prioritizing-uses-of-covid-19-vaccines>. Accessed on March 24th 2022.
- Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N, Mizrahi B, Alroy-Preis S, Ash N, Milo R, Huppert A. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. *N Engl J Med*. 2021;385(15):1393–400. <https://doi.org/10.1056/NEJMoa2114255>.

17. Fares S, Elmnyer MM, Mohamed SS, Elsayed R. COVID-19 vaccination perception and attitude among healthcare workers in Egypt. *J Prim Care Community Health*. 2021;12:21501327211013304. <https://doi.org/10.1177/21501327211013303>.
18. Hatmal MM, Al-Hatamleh MA, Olaimat AN, Hatmal M, Alhaj-Qasem DM, Olaimat TM, Mohamud R. Side effects and perceptions following COVID-19 vaccination in Jordan: a randomized, cross-sectional study implementing machine learning for predicting severity of side effects. *Vaccines*. 2021;9(6):556. <https://doi.org/10.3390/vaccines9060556>.
19. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *N Engl J Med*. 2021;384(5):403–16. <https://doi.org/10.1056/NEJMoa2035389>.
20. Ministry of Health (MOH) Malaysia National COVID-19 Immunisation Programme the Special Committee for Ensuring Access to COVID-19 Vaccine Supply (Jkjav) 2021; Ministry of Health (MOH): Kuala Lumpur, Malaysia, 2021.
21. El-Sokkary RH, El Seifi OS, Hassan HM, Mortada EM, Hashem MK, Gadelrab MR, Tash RM. Predictors of COVID-19 vaccine hesitancy among Egyptian healthcare workers: a cross-sectional study. *BMC Infect Dis*. 2021;21(1):1–9. <https://doi.org/10.1186/s12879-021-06392-1>.
22. Elgendy MO, El-Gendy AO, Alzarea AI, Mahmoud S, Alqahtani SS, Fahmy AM, El-Seedi HR, Sayed AM, Alatawi AD, Abdelrahim ME, Alanazi AS. SARS-CoV-2 post vaccinated adverse effects and efficacy in the Egyptian Population. *Vaccines*. 2021;10(1):18. <https://doi.org/10.3390/vaccines10010018>.
23. World Health Organization. Egypt. <https://covid19.who.int/region/emro/country/eg>. Accessed on May 5th 2022.
24. Kim MH, Son NH, Park YS, Lee JH, Kim DA, Kim YC. Effect of a hospital-wide campaign on COVID-19 vaccination uptake among healthcare workers in the context of raised concerns for life-threatening side effects. *PLoS ONE*. 2021;16(10):e0258236. <https://doi.org/10.1371/journal.pone.0258236>.
25. Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, McClung N, Campos-Outcalt D, Morgan RL, Mbaeyi S, Romero JR. The advisory committee on immunization practices' interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine—United States, December 2020. *MMWR*. 2020;69(50):1922. <https://doi.org/10.15585/mmwr.mm6950e2>.
26. Kadali RA, Janagama R, Peruru S, Malayala SV. Side effects of BNT162b2 mRNA COVID-19 vaccine: a randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers. *IJID*. 2021;106:376–81. <https://doi.org/10.1016/j.ijid.2021.04.047>.
27. Soiza RL, Scicluna C, Thomson EC. Efficacy and safety of COVID-19 vaccines in older people. *Age Ageing*. 2021;50(2):279–83. <https://doi.org/10.1093/ageing/afaa274>.
28. Dziedzic A, Riad A, Attia S, Klugar M, Tanasiewicz M. Self-reported adverse events of COVID-19 vaccines in polish healthcare workers and medical students. Cross-sectional study and pooled analysis of CoVaST project results in central Europe. *J Clin Med*. 2021;10(22):5338. <https://doi.org/10.3390/jcm10225338>.
29. Tobaigy M, Elkout H, MacLure K. Analysis of thrombotic adverse reactions of COVID-19 AstraZeneca vaccine reported to EudraVigilance database. *Vaccines*. 2021;9(4):393. <https://doi.org/10.3390/vaccines9040393>.
30. WHO Official Website. Draft Landscape of COVID-19 Candidate Vaccines. Available online: <https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines> (accessed on March 3rd 2021).
31. EMA Recommends COVID-19 Vaccine AstraZeneca for Authorisation in the EU. Available online: <https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-astrazeneca-authorisation-eu> (accessed on March 3rd 2021).
32. Wise J. COVID-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots. *BMJ*. 2021;372: n699. <https://doi.org/10.1136/bmj.n699>.
33. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. *N Engl J Med*. 2021;384(22):2092–101. <https://doi.org/10.1056/NEJMoa2104840>.
34. World Health Organization. Annexes to the interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotech Group (CNBG), Sinopharm: grading of evidence: evidence to recommendation tables, first issued May 7th 2021, updated October 28th 2021 (No. WHO/2019-nCoV/vaccines/SAGE\_recommendation/BIBP/annexes/2021.2). World Health Organization; 2021.
35. Raude J, Fressard L, Gautier A, Pulcini C, Peretti-Watel P, Verger P. Opening the "Vaccine Hesitancy" black box: how trust in institutions affects French GPs' vaccination practices. *Expert Rev Vaccines*. 2016;15(7):937–48. <https://doi.org/10.1080/14760584.2016.1184092>.
36. Jęśkowiak I, Wiatrak B, Grosman-Dziewiszek P, Szeląg A. The incidence and severity of post-vaccination reactions after vaccination against COVID-19. *Vaccines*. 2021;9(5):502. <https://doi.org/10.3390/vaccines9050502>.
37. Bauernfeind S, Hitzgenbichler F, Huppertz G, Zeman F, Koller M, Schmidt B, Plentz A, Bauswein M, Mohr A, Salzberger B. Brief report: attitudes towards Covid-19 vaccination among hospital employees in a tertiary care university hospital in Germany in December 2020. *Infection*. 2021;49(6):1307–11. <https://doi.org/10.1007/s15010-021-01622-9>.
38. Szmyd B, Karuga FF, Bartoszek A, Stanięcka K, Siwecka N, Bartoszek A, Błaszczak M, Radek M. Attitude and behaviors towards SARS-CoV-2 vaccination among healthcare workers: a cross-sectional study from Poland. *Vaccines*. 2021;9(3):218. <https://doi.org/10.3390/vaccines9030218>.
39. Freeman D, Loe BS, Chadwick A, Vaccari C, Waite F, Rosebrock L, Jenner L, Petit A, Lewandowsky S, Vanderslott S, Innocenti S. COVID-19 vaccine hesitancy in the UK: the Oxford coronavirus explanations, attitudes, and narratives survey (Oceans) II. *Psychol Med*. 2020. <https://doi.org/10.1017/S0033291720005188>.
40. Babicki M, Mastalerz-Migas A. Attitudes toward vaccination against COVID-19 in Poland. A longitudinal study performed before and two months after the commencement of the population vaccination programme in Poland. *Vaccines*. 2021;9(5):503. <https://doi.org/10.3390/vaccines9050503>.
41. Khadka S, Yuchi A, Shrestha DB, Budhathoki P, Al-Subari SM, Alhouzani TZ, Butt AI. Repurposing drugs for COVID-19: an approach for treatment in the pandemic. *Altern Ther Health Med*. 2020;26(S2):100–7.
42. Zahid MN. Unfolding the mild to moderate short-term side effects of four COVID-19 vaccines used in Bahrain: a cross-sectional study. *Vaccines*. 2021;9(11):1369. <https://doi.org/10.3390/vaccines9111369>.
43. Riad A, Pokorná A, Attia S, Klugarová J, Koščik M, Klugar M. Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech Republic. *J Clin Med*. 2021;10(7):1428. <https://doi.org/10.3390/jcm10071428>.
44. Hatmal MM, Al-Hatamleh MA, Olaimat AN, Mohamud R, Fawaz M, Kateeb ET, Alkhairy OK, Tayyem R, Lounis M, Al-Raei M, Dana RK. Reported adverse effects and attitudes among Arab populations following COVID-19 vaccination: a large-scale multinational study implementing machine learning tools in predicting post-vaccination adverse effects based on predisposing factors. *Vaccines*. 2022;10(3):366. <https://doi.org/10.3390/vaccines10030366>.
45. Saeed BQ, Al-Shahrabi R, Alhaj SS, Alkakhari ZM, Adrees AO. Side effects and perceptions following Sinopharm COVID-19 vaccination. *IJID*. 2021;111:219–26. <https://doi.org/10.1016/j.ijid.2021.08.013>.
46. Serap BA, Burucu R, Cantekin I, Dönmez H. Determining the side effects of COVID-19 (Sinovac) vaccination on nurses: an independent descriptive study. *Konuralp Med J*. 13(51):479–87.
47. Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, Yang X. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: Interim analysis of 2 randomized clinical trials. *JAMA*. 2021;324(10):951–60. <https://doi.org/10.1001/jama.2020.15543>.
48. Almufty HB, Mohammed SA, Abdullah AM, Merza MA. Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study. *Diabetes Metab Syndr Clin Res Rev*. 2021;15(5): 102207. <https://doi.org/10.1016/j.dsx.2021.102207>.
49. Di Resta C, Ferrari D, Viganò M, Moro M, Sabetta E, Minerva M, Ambrosio A, Locatelli M, Tomaiuolo R. The gender impact assessment among healthcare workers in the SARS-CoV-2 vaccination—an analysis of serological response and side effects. *Vaccines*. 2021;9(5):522. <https://doi.org/10.3390/vaccines9050522>.
50. Klugar M, Riad A, Mekhemar M, Conrad J, Buchbender M, Howaldt HP, Attia S. Side effects of mRNA-based and viral vector-based COVID-19 vaccines among German healthcare workers. *Biology*. 2021;10(8):752. <https://doi.org/10.3390/biology10080752>.
51. Mohsin M, Mahmud S, Mian AU, Hasan P, Muyeed A, Islam A, Rahman MM, Islam M, Khan HR, Rahman MS. Side effects of COVID-19 vaccines

and perceptions about COVID-19 and its vaccines in Bangladesh. medRxiv. 2022.

52. Luxi N, Giovanazzi A, Capuano A, Crisafulli S, Cutroneo PM, Fantini MP, Ferrajolo C, Moretti U, Poluzzi E, Raschi E, Ravaldi C. COVID-19 vaccination in pregnancy, paediatrics, immunocompromised patients, and persons with history of allergy or prior SARS-CoV-2 infection: overview of current recommendations and pre-and post-marketing evidence for vaccine efficacy and safety. *Drug Saf.* 2021;44(12):1247–69. <https://doi.org/10.1007/s40264-021-01131-6>.
53. Negahdaripour M, Shafiekhani M, Moezzi SM, Amiri S, Rasekh S, Bagheri A, Mosaddeghi P, Vazin A. Administration of COVID-19 vaccines in immunocompromised patients. *Int Immunopharmacol.* 2021;99: 108021. <https://doi.org/10.1016/j.intimp.2021.108021>.

### Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

